Hypothesis: What is the Best We Can Do with Hydroxychloroquine for COVID-19?

被引：2

作者：

Wang, Shuncong ^{[1
]}

Mulier, Stefaan ^{[1
,2
]}

Jonscher, Charles ^{[3
]}

Ye, Sheng ^{[4
]}

Chen, Lei ^{[1
]}

Feng, Yuanbo ^{[1
]}

Li, Yue ^{[5
]}

Ni, Yicheng ^{[1
]}

机构：

[1] KU, Grp Biomed Sci, Campus Gasthuisberg, Leuven, Belgium

[2] Delta Hosp, Dept Surg, Brussels, Belgium

[3] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA

[4] Primary Care NJ, Englewood, NJ USA

[5] Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai 201318, Peoples R China

来源：

CLINICAL EPIDEMIOLOGY | 2020年 / 12卷

关键词：

COVID-19; pandemic; early treatment; hydroxychloroquine; lockdown; SARS-COV-2;

D O I：

10.2147/CLEP.S277889

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

There are widespread anecdotal reports of seemingly successful treatment among the early (three to seven days from symptoms) stage coronavirus disease 2019 (COVID-19) patients with the drug hydroxychloroquine (HCQ), and randomized placebo-controlled trials of HCQ in outpatient settings are underway. In this note, we (1) report observational evidence and present scientific reasoning as to why early treatment with HCQ may succeed while treatment later in the disease progression is likely to fail and (2) hypothesize a public health regime under which HCQ may be used to mitigate the impact of the current pandemic.

引用

页码：1139 / 1144

页数：6

共 37 条

[1] Treatment of SARS-CoV-2: How far have we reached?
Ahsan, Waquar
Javed, Shamama
Al Bratty, Mohammed
Alhazmi, Hassan A.
Najmi, Asim
[J]. DRUG DISCOVERIES AND THERAPEUTICS, 2020, 14 (02) : 67 - 72
[2] Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility
Arons, M. M.
Hatfield, K. M.
Reddy, S. C.
Kimball, A.
James, A.
Jacobs, J. R.
Taylor, J.
Spicer, K.
Bardossy, A. C.
Oakley, L. P.
Tanwar, S.
Dyal, J. W.
Harney, J.
Chisty, Z.
Bell, J. M.
Methner, M.
Paul, P.
Carlson, C. M.
McLaughlin, H. P.
Thornburg, N.
Tong, S.
Tamin, A.
Tao, Y.
Uehara, A.
Harcourt, J.
Clark, S.
Brostrom-Smith, C.
Page, L. C.
Kay, M.
Lewis, J.
Montgomery, P.
Stone, N. D.
Clark, T. A.
Honein, M. A.
Duchin, J. S.
Jernigan, J. A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22) : 2081 - 2090
[3] SARS-CoV-2: Olfaction, Brain Infection, and the Urgent Need for Clinical Samples Allowing Earlier Virus Detection
Butowt, Rafal
Bilinska, Katarzyna
[J]. ACS CHEMICAL NEUROSCIENCE, 2020, 11 (09): : 1200 - 1203
[4] Carlucci P., 2020, HYDROXYCHLOROQUINE A, DOI [10.1101/2020.05.02.20080036, 10.1101/2020.05.02.20080036v1, DOI 10.1101/2020.05.02.20080036V1]
[5] The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin
Chorin, Ehud
Dai, Matthew
Shulman, Eric
Wadhwani, Lalit
Bar-Cohen, Roi
Barbhaiya, Chirag
Aizer, Anthony
Holmes, Douglas
Bernstein, Scott
Spinelli, Michael
Park, David S.
Chinitz, Larry A.
Jankelson, Lior
[J]. NATURE MEDICINE, 2020, 26 (06) : 808 - 809
[6] Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection
Fantini, Jacques
Di Scala, Coralie
Chahinian, Henri
Yahi, Nouara
[J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (05)
[7] Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19
Gandhi, Monica
Yokoe, Deborah S.
Havlir, Diane V.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22) : 2158 - 2160
[8] Responding to Covid-19-A Once-in-a-Century Pandemic?
Gates, Bill
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (18) : 1677 - 1679
[9] Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
Geleris, Joshua
Sun, Yifei
Platt, Jonathan
Zucker, Jason
Baldwin, Matthew
Hripcsak, George
Labella, Angelena
Manson, Daniel K.
Kubin, Christine
Barr, R. Graham
Sobieszczyk, Magdalena E.
Schluger, Neil W.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25) : 2411 - 2418
[10] Hoffman Tove, 2020, Infection Ecology & Epidemiology, V10, P1754538, DOI 10.1080/20008686.2020.1754538

← 1 2 3 4 →